The abstract is read at the publisher; the summary is JClub's.
In 48 patients with psoriatic arthritis initiating GLP-1 receptor agonists, weight fell by -6.43 kg (95% CI -9.5 to -2.0; P < 0.0001) and inflammatory and metabolic markers improved.
- Why it matters: Obesity is common in psoriatic arthritis and linked to worse outcomes, but the effect of GLP-1RA therapy on PsA activity and cardiometabolic health is unclear.
- What they did: This retrospective cohort compared clinical visits within one year before versus after GLP-1RA initiation, tracking weight, PsA activity measures, and cardiometabolic parameters, including associations per 1% weight reduction.
- The result: Posttreatment C-reactive protein (-1.1 mg/L; P = 0.002), pain (-1.0; P = 0.01), and triglycerides (-0.35 mmol/L; P = 0.02) decreased, and greater weight loss predicted better Disease Activity in Psoriatic Arthritis and tender joint count.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.